Safest Antihypertensive Medications During Breastfeeding

First-Line Medication Options

The American Heart Association recommends nifedipine, amlodipine, enalapril, and labetalol as first-line agents for the treatment of postpartum hypertension regardless of breastfeeding status 1, 2, 3
Extended-release nifedipine is considered a first-choice medication for breastfeeding mothers due to its once-daily dosing convenience and safety profile 1, 3
Amlodipine is also safe during breastfeeding with minimal excretion in breast milk (median relative infant dose of 4.2%, well below the concerning threshold of 10%) 3

Diuretics may reduce milk volume and thereby suppress lactation, especially at higher doses, according to the American Heart Association 3, 4, 5
Atenolol should be avoided due to risk of fetal growth restriction if pregnancy occurs, as recommended by the American Heart Association 2

For mothers with mild hypertension (stage 1) who plan to breastfeed for only a few months, it might be reasonable to withhold antihypertensive medication with close BP monitoring, as suggested by the American Heart Association 4, 5
If the mother has reduced ejection fraction (40-50%), combination therapy including a beta-blocker and ACE inhibitor may be appropriate, with consideration of lactation preferences, according to the American Heart Association 3
All breastfed infants of mothers taking antihypertensive agents should be monitored for potential adverse effects, as recommended by the American Heart Association 4, 5

The American Heart Association recommends the following algorithm for medication selection:

Using diuretics at high doses, which may affect milk production, as warned by the American Heart Association 3, 4
Failing to monitor the breastfed infant for potential adverse effects, as recommended by the American Heart Association 4, 5
Not considering the dosing frequency, which affects medication adherence (once-daily options like nifedipine, amlodipine, and enalapril are preferred over multiple daily dosing options), according to the American Heart Association 2, 3

The European Society of Cardiology guidelines list additional compatible medications, including other ACE inhibitors (benazepril, captopril, quinapril), calcium channel blockers (diltiazem, verapamil), and beta-blockers (metoprolol, nadolol, propranolol, timolol), for use in breastfeeding mothers 6

The European guidelines note that methyldopa should be used cautiously in women at risk of developing depression 6

Diuretics (furosemide, hydrochlorothiazide, spironolactone) may reduce milk volume and suppress lactation, especially at higher doses, and are generally not preferred in breastfeeding women, according to the European Society of Cardiology guidelines 6

Blood pressure should be checked at 6 weeks postpartum with 24-hour ambulatory monitoring to confirm persistent hypertension, as recommended by the European Society of Cardiology guidelines 6

The European Society of Cardiology recommends beta-1 selective agents like metoprolol over non-selective beta-blockers during lactation for heart failure treatment, with metoprolol being the preferred beta-blocker for breastfeeding women with hypertension or heart failure 7
The American College of Cardiology, along with the American Heart Association and the Heart Failure Society of America, recommends metoprolol as the preferred beta-blocker during lactation, with specific instructions to monitor neonatal heart rate, for both hypertension and heart failure management in the postpartum period 8

The European Society of Cardiology states that newborns should be supervised for 24-48 hours after delivery to exclude hypoglycemia, bradycardia, and respiratory depression, and ongoing monitoring of the breastfed infant should focus on heart rate changes and weight gain patterns 7
The American College of Cardiology recommends monitoring heart rate changes in breastfed infants of mothers taking metoprolol 8

For heart failure in lactating women, the European Society of Cardiology and the American College of Cardiology recommend continuing or initiating metoprolol as part of guideline-directed medical therapy 7, 8
The European Society of Cardiology recommends avoiding atenolol during lactation due to its higher concentration in breast milk and greater risk to the infant, and instead preferring metoprolol as the beta-blocker of choice 7
The European Society of Cardiology and the American College of Cardiology recommend not discontinuing necessary beta-blocker therapy solely due to breastfeeding, as metoprolol's safety profile supports continuation, and ensuring ACE inhibitors, ARBs, and aldosterone antagonists are avoided during pregnancy but can be added postpartum if needed for heart failure 7, 8